Reconcile is a chewable, flavored tablet that contains fluoxetine hydrochloride. Reconcile chewable tablets are available in 8, 16, 32, and 64 mg tablet strengths for oral administration to dogs.
The recommended dose of
Reconcile chewable tablets is 1-2 mg/kg (0.5-0.9 mg/lb) administered
once daily, in conjunction with a behavior modification plan. A typical
behavior modification plan consists of the pet owner implementing
standard training techniques based on principles such as rewarding
appropriate behavior; coming and going in a manner that does not elicit
inappropriate responses from the dog; and teaching the dog to be content
while alone.
Recommended Dose of RECONCILE Chewable Tablets
Dog Weight |
No. of
Tablets/day |
Tablet Strength
(mg) |
(lb) |
(kg) |
8.8 - 17.6 |
4.0 - 8.0 |
1 |
8 |
17.7 - 35.2 |
8.1 -16.0 |
1 |
16 |
35.3 - 70.4 |
16.1 - 32.0 |
1 |
32 |
70.5 - 140.8 |
32.1 - 64.0 |
1 |
64 |
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian
Reconcile Chewable Tablets
are readily consumed by dogs or can be administered like other tablet
medications, and can be given with or without food.
Professional discretion
should be used in determining the need for dose reduction in the event
of a possible adverse reaction. Approximately half of patients tolerate
a return to the previous dose after 1-2 weeks on a reduced schedule.
If a dose is missed, the
next scheduled dose should be administered as prescribed. Do not
increase or double the dose.
Contraindications:
Reconcile chewable tablets
are contraindicated for use in dogs with epilepsy or a history of
seizures. Reconcile chewable tablets should not be given concomitantly
with drugs that lower the seizure threshold (e.g., phenothiazines such
as acepromazine or chlorpromazine).
Reconcile chewable tablets
should not be given in combination with a monoamine oxidase inhibitor (MAOI)
[e.g., selegiline hydrochloride (L-deprenyl) or amitraz], or within a
minimum of 14 days of discontinuing therapy with an MAOI.
Reconcile chewable tablets
are contraindicated in dogs with a known hypersensitivity to fluoxetine
HCl or other SSRIs.
Because fluoxetine and its
major metabolite, norfluoxetine, have long half-lives, a 6-week washout
interval should be observed following discontinuation of therapy with Reconcile chewable tablets prior to the administration of any drug that
may adversely interact with fluoxetine or norfluoxetine.
Precautions:
Reconcile chewable tablets
are not recommended for the treatment of aggression. Reconcile chewable
tablets have not been clinically tested for the treatment of other
behavioral disorders. Studies to determine the effects of Reconcile chewable tablets in breeding, pregnant, or lactating dogs and in
patients less than 6 months of age have not been conducted.
Seizures may occur in dogs
treated with Reconcile chewable tablets, even in dogs without a history
of epilepsy or seizures.
Before prescribing Reconcile chewable tablets, a comprehensive physical examination should
be conducted to rule out causes of inappropriate behavior unrelated to
separation anxiety. The examination should include a thorough history
and assessment of the patient's household environment and standard
practice laboratory tests as appropriate for the patient's age and
health status. Veterinarians should be familiar with the risks and
benefits of the treatment of behavioral disorders in dogs before
initiating therapy. Inappropriate use of Reconcile chewable tablets,
i.e. in the absence of a diagnosis or without concurrent behavior
modification, may expose the animal to unnecessary adverse reactions and
may not provide any lasting benefit of therapy.
Reconcile chewable tablets
have not been evaluated with drugs that affect the cytochrome P450
enzyme system. Reconcile chewable tablets should be used with caution
when co-administered with any drug that affects the cytochrome P450
enzyme system (for example, ketoconazole). Studies to assess the
interaction of Reconcile chewable tablets with tricyclic antidepressants
(TCAs) (for example, amitriptyline and clomipramine) have not been
conducted. The minimum washout period to transition dogs from TCAs to Reconcile chewable tablets has not been evaluated. Published
pharmacokinetic data demonstrates that TCAs are cleared 4 days following
discontinuation.
Clinical Pharmacology:
Fluoxetine exerts its
effect by inhibiting the reuptake of serotonin at the pre-synaptic
neuron. Fluoxetine does not act as a sedative. Fluoxetine is well
absorbed after oral administration (~72%). It is largely metabolized in
the liver by cytochrome P-450 enzyme system to norfluoxetine, an
equipotent SSRI that contributes to the efficacy of Reconcile chewable
tablets.
Eli Lilly and Company